Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
Competitive Landscape of the NSAIDs Market
In no particular order of rank
Competitive Landscape of the NSAIDs Market
The NSAIDs market is highly competitive, with numerous global players offering a wide range of products. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the market with established brands like Advil, Aleve, and Aspirin. Competition is based on factors such as product innovation, safety profiles, pricing, and distribution networks. Emerging companies are focusing on developing safer, more effective NSAID formulations, while larger companies maintain their leadership through strong brand recognition and extensive distribution channels.
In February 2024, Hikma Pharmaceuticals introduced COMBOGESIC IV in the U.S., offering an opioid-free alternative for adult pain management. COMBOGESIC IV combines acetaminophen (1,000 mg) and ibuprofen (300 mg) for intravenous use, receiving FDA approval in October 2023 for treating mild to moderate pain, with an adjunctive role in severe pain alongside opioids. This dual-action solution aligns with the American Society of Anesthesiology’s multimodal pain management strategy, offering quicker and sustained pain relief. Developed by AFT Pharmaceuticals, COMBOGESIC IV is also marketed globally as MAXIGESIC IV. (Source: https://www.hikma.com/news/hikma-announces-us-launch-of-combogesic-iv/) In December 2023, Scilex Holding Company submitted a New Drug Submission to Health Canada for ELYXYB (celecoxib oral solution), intended to treat acute migraines. ELYXYB is the only FDA-approved oral solution for migraines, offering pain relief within 15 minutes. With the Canadian migraine therapeutics market expected to reach USD 400 million by 2025, Scilex anticipates approval within a year. The company aims to provide an alternative for patients who are not responsive to triptan therapies. (Source: https://scilexholding.gcs-web.com/news-releases/news-release-details/scilex-holding-company-announces-filing-new-drug-submission-nds)
Click any bar or cell to request the full company profile
Company
2022 (A)
2023 (A)
2024 (A)
2025 (A)
Pfizer Inc.
•••
•••
•••
•••
Johnson & Johnson
•••
•••
•••
•••
Novartis AG
•••
•••
•••
•••
GlaxoSmithKline plc
•••
•••
•••
•••
Bayer AG
•••
•••
•••
•••
Sanofi S.A.
•••
•••
•••
•••
Abbott Laboratories
•••
•••
•••
•••
Merck & Co.
•••
•••
•••
•••
Inc.
•••
•••
•••
•••
Amgen Inc.
•••
•••
•••
•••
Mylan N.V.
•••
•••
•••
•••
Teva Pharmaceutical Industries Ltd.
•••
•••
•••
•••
Aurobindo Pharma
•••
•••
•••
•••
Cipla Limited
•••
•••
•••
•••
Sun Pharmaceutical Industries Ltd.
•••
•••
•••
•••
Mallinckrodt Pharmaceuticals
•••
•••
•••
•••
Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.
According to Cognitive Market Research, the global NSAIDs market size was USD 18542.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 7417.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5562.75 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 4264.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 927.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 370.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The aspirin is the fastest growing segment of the NSAIDs industry
Introduction of the NSAIDs Market
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are widely used medications to alleviate pain, reduce inflammation, and lower fever. These drugs work by inhibiting cyclooxygenase (COX) enzymes, which are responsible for the production of prostaglandins, substances involved in inflammation. NSAIDs are available in various types, including aspirin, ibuprofen, naproxen, and nabumetone, each with distinct pharmacological profiles. They are prescribed for a variety of conditions, such as arthritis, migraine, and ophthalmic diseases. NSAIDs can be administered orally, topically, or via other routes, and they are distributed through hospital pharmacies, retail pharmacies, and online platforms.
In April 2024, Glenmark Pharmaceuticals received approval from the U.S. FDA for its Acetaminophen and Ibuprofen Tablets (250 mg/125 mg), which will be sold as an over-the-counter product. This formulation is bioequivalent to Haleon’s Advil Dual Action with Acetaminophen, which earned approximately USD 84.1 million in sales over the past year. Glenmark plans to strengthen its portfolio with 195 approved products in the U.S. and 52 ANDAs pending. The company focuses on respiratory, dermatology, and oncology treatments and operates across 11 manufacturing facilities worldwide. (Source: https://glenmarkpharma-us.com/press/glenmark-pharmaceuticals-receives-anda-approval-for-acetaminophen-and-ibuprofen-tablets-250-mg-125-mg-otc/)
NSAIDs Market Insights Video
Conclusion
The global NSAIDs market will expand significantly by 6.50% CAGR between 2024 and 2031.
Rising incidence of osteoarthritis, coupled with an aging population, will drive demand for NSAIDs in arthritis treatment, boosting sales for both prescription and over-the-counter options.
With growing preference for localized treatment, especially for conditions like back pain and arthritis, the sales of topical NSAIDs will increase as they offer fewer systemic side effects.
Analyst Conclusion
Conclusion
The global NSAIDs market will expand significantly by 6.50% CAGR between 2024 and 2031.
Rising incidence of osteoarthritis, coupled with an aging population, will drive demand for NSAIDs in arthritis treatment, boosting sales for both prescription and over-the-counter options.
With growing preference for localized treatment, especially for conditions like back pain and arthritis, the sales of topical NSAIDs will increase as they offer fewer systemic side effects.
Supriya Yadav
Research Analyst · Cognitive Market Research
As a Research Analyst, I bring over two years of experience in market research, data analysis, and market estimation. I specialize in turning complex datasets into meaningful insights that help businesses identify opportunities, understand market dynamics, and make confident, growth-focused decisions.
My expertise spans across analyzing industry trends, forecasting market potential, mapping competitive landscapes, and studying consumer behavior to deliver actionable recommendations. With an MBA in Marketing and Finance, I combine strong analytical skills with strategic thinking, ensuring that every project I work on contributes real value to clients.
I am passionate about using research to uncover patterns, anticipate shifts, and deliver insights that drive measurable business impact. My goal is to continuously learn, innovate, and provide data-driven solutions that empower clients to succeed in a competitive environment.
The global market size for NSAIDs in 2024 is USD 18542.5 million.
The global NSAIDs market is expected to grow with a CAGR of 6.50% over the projected period.
North America held a significant global NSAIDs market revenue share in 2024.
Asia-Pacific will witness the fastest growth of the global NSAIDs market over the coming years.
The US had the most significant global NSAIDs market revenue share in 2024.
The main driver of the growth of the NSAIDs market are increasing prevalence of chronic pain disorders, growing geriatric population, and rising demand for over-the-counter medications.
The osteoarthritis treatment dominates the market.
★ Reviews
No reviews yet — be the first!
Rate this report
NSAIDs — Table of Contents
Disclaimer: Redacted sample for representative purposes. Charts and data do not depict actual statistics. TOC varies by license selection.
License Edition
Country
End Use Outlook:
Back Pain Treatment, Osteoarthritis Treatment, Other Disease Treatment
18.6 Future Gross Margin Outlook and Profitability Trends
19.1 Key Takeaways
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study.
You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
19.2 Analyst Point of View
19.3 Assumptions and Acronyms
20.1 Primary Data Collection
20.1.1 Steps for Primary Data Collection
20.1.1.1 Identification of KOL
20.1.2 Backward Integration
20.1.3 Forward Integration
20.1.4 How Primary Research Help Us
20.1.5 Modes of Primary Research
20.2 Secondary Research
20.2.1 How Secondary Research Help Us
20.2.2 Sources of Secondary Research
20.3 Data Validation
20.3.1 Data Triangulation
20.3.2 Top Down & Bottom Up Approach
20.3.3 Cross check KOL Responses with Secondary Data
20.4 Data Representation
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the NSAIDs Market analysis.
01
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
02
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
03
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
04
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
05
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the NSAIDs market.
Service 01
Market Survey
B2BB2C
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the nsaids ecosystem — validated by our global panel of 10,000+ industrial respondents.
What's Included
Buyer intent & sentiment analysis
Purchase cycle mapping
Price sensitivity research
Channel preference profiling
Competitive perception study
Most Requested
Service 02
Customized Market Data & Reports
CustomReady Report
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
What's Included
Ready syndicate report (250+ pages)
Custom data scope & segmentation
Excel quantitative models
Board-ready PPT with key findings
Secure cloud portal access
Service 03
Strategic Consultation
With SurveyWith Report
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
What's Included
Dedicated analyst assigned to you
Live walkthrough of findings
Strategic Q&A sessions
Go-to-market recommendations
NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
